DOP2009000223A - Anticuerpos anti-esclerostina - Google Patents

Anticuerpos anti-esclerostina

Info

Publication number
DOP2009000223A
DOP2009000223A DO2009000223A DO2009000223A DOP2009000223A DO P2009000223 A DOP2009000223 A DO P2009000223A DO 2009000223 A DO2009000223 A DO 2009000223A DO 2009000223 A DO2009000223 A DO 2009000223A DO P2009000223 A DOP2009000223 A DO P2009000223A
Authority
DO
Dominican Republic
Prior art keywords
antibodies
bone
sclerostine
sclerostine antibodies
osteoporosis
Prior art date
Application number
DO2009000223A
Other languages
English (en)
Inventor
Andrew Ihor Korytko
David Matthew Marquis
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2009000223A publication Critical patent/DOP2009000223A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos humanizados y quimericos que enlazan especificamente esclerostina humana y son caracterizados por tener propiedades neutralizantes fuertes y alta afinidad. Los anticuerpos de la invención son utiles para incrementar la masa ósea, densidad mineral ósea y consistencia ósea, para el tratamiento de varios trastornos, por ejemplo, osteoporosis, en un sujeto humano.
DO2009000223A 2007-03-20 2009-09-18 Anticuerpos anti-esclerostina DOP2009000223A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20

Publications (1)

Publication Number Publication Date
DOP2009000223A true DOP2009000223A (es) 2009-10-15

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000223A DOP2009000223A (es) 2007-03-20 2009-09-18 Anticuerpos anti-esclerostina

Country Status (32)

Country Link
US (3) US7744874B2 (es)
EP (2) EP2131860B1 (es)
JP (2) JP2010524846A (es)
KR (1) KR101123487B1 (es)
CN (1) CN101646457B (es)
AU (1) AU2008229141B2 (es)
BR (1) BRPI0809026A2 (es)
CA (1) CA2682212C (es)
CO (1) CO6230999A2 (es)
CR (1) CR11004A (es)
CY (1) CY1114784T1 (es)
DK (1) DK2131860T3 (es)
DO (1) DOP2009000223A (es)
EA (1) EA018204B1 (es)
EC (1) ECSP099658A (es)
ES (1) ES2446293T3 (es)
HK (1) HK1138790A1 (es)
HR (1) HRP20140108T1 (es)
IL (1) IL200437A0 (es)
MA (1) MA31308B1 (es)
MX (1) MX2009010051A (es)
MY (1) MY149129A (es)
NZ (1) NZ578870A (es)
PL (1) PL2131860T3 (es)
PT (1) PT2131860E (es)
RS (1) RS53157B (es)
SI (1) SI2131860T1 (es)
SV (1) SV2009003374A (es)
TN (1) TN2009000383A1 (es)
UA (1) UA96474C2 (es)
WO (1) WO2008115732A2 (es)
ZA (1) ZA200906345B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69942782D1 (de) 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ES2666650T3 (es) 2006-12-29 2018-05-07 OstéoQC Inc. Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise
SI2131860T1 (sl) * 2007-03-20 2014-02-28 Eli Lilly And Company Protitelesa proti sklerostinu
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
JP2011506483A (ja) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
RU2012148716A (ru) 2010-04-16 2014-05-27 Новартис Аг Способы и композиции для улучшения оссеоинтеграции имплантата
JP5889877B2 (ja) 2010-05-14 2016-03-30 アムジエン・インコーポレーテツド 高濃度抗体製剤
AU2011267869A1 (en) * 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
EP4116325A1 (en) 2010-11-05 2023-01-11 Novartis AG Methods of treating rheumatoid arthritis using il-17 antagonists
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
EA029956B1 (ru) 2011-03-25 2018-06-29 Эмджен Инк. Кристаллы антител против склеростина и составы на их основе
ES2685479T3 (es) 2011-04-19 2018-10-09 Amgen Inc. Método para el tratamiento de la osteoporosis
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
BR112014009799A2 (pt) 2011-10-24 2017-06-13 Abbvie Inc imunoligantes dirigidos conra tnf
SG11201401791WA (en) * 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
EP2771361A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Bispecific immunobinders directed against tnf and il-17
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
CN104619342A (zh) * 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
KR102584953B1 (ko) * 2015-03-13 2023-10-04 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항 스클레로스틴 항체, 이의 항원 결합 단편 및 의학적 용도
BR112018067522A2 (pt) 2016-03-01 2019-02-05 Univ Of Rijeka Faculty Of Medicine anticorpos específicos para receptor de poliovírus humano (pvr)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
AU2017310412A1 (en) 2016-08-08 2019-02-21 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
JP7246306B2 (ja) * 2016-10-28 2023-03-27 イーライ リリー アンド カンパニー 抗ｒａｎｋｌ抗体およびその使用
AU2017354070A1 (en) * 2016-11-01 2019-05-16 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (PD-1)
DK3478719T3 (da) * 2016-12-21 2021-03-01 Mereo Biopharma 3 Ltd Anvendelse af anti-sclerostin-antistoffer i behandlingen af osteogenesis imperfecta
BR112019014187A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-pd-1
WO2018139623A1 (en) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
TW201909913A (zh) 2017-07-27 2019-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種ｓｏｓｔ抗體醫藥組成物及其用途
BR112020020080A2 (pt) 2018-03-30 2021-01-05 Amgen Inc Variantes de anticorpos c-terminais
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
US20210308265A1 (en) 2018-08-10 2021-10-07 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
EP3883971A1 (en) * 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
EP4013786A1 (en) 2019-08-12 2022-06-22 Amgen Inc. Anti-sclerostin antibody formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE69942782D1 (de) 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
WO2004047609A2 (en) * 2002-11-27 2004-06-10 Visiopharm Aps A method and a system for establishing a quantity measure for joint destruction
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
AU2004324464A1 (en) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc. Methods of optimizing antibody variable region binding affinity
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
SI2131860T1 (sl) * 2007-03-20 2014-02-28 Eli Lilly And Company Protitelesa proti sklerostinu

Also Published As

Publication number Publication date
US8257704B2 (en) 2012-09-04
US20110250205A1 (en) 2011-10-13
EP2131860A2 (en) 2009-12-16
EA018204B1 (ru) 2013-06-28
JP2013151504A (ja) 2013-08-08
CN101646457A (zh) 2010-02-10
MA31308B1 (fr) 2010-04-01
CN101646457B (zh) 2013-05-01
SV2009003374A (es) 2011-01-10
KR101123487B1 (ko) 2012-03-23
HK1138790A1 (en) 2010-09-03
WO2008115732A2 (en) 2008-09-25
TN2009000383A1 (en) 2010-12-31
AU2008229141B2 (en) 2013-02-07
EP2131860B1 (en) 2013-12-18
HRP20140108T1 (hr) 2014-02-28
DK2131860T3 (da) 2014-01-13
ZA200906345B (en) 2010-11-24
EP2664346A1 (en) 2013-11-20
PL2131860T3 (pl) 2014-05-30
WO2008115732A3 (en) 2008-12-11
CO6230999A2 (es) 2010-12-20
ECSP099658A (es) 2009-10-30
CA2682212C (en) 2014-05-06
UA96474C2 (en) 2011-11-10
KR20090114462A (ko) 2009-11-03
AU2008229141A1 (en) 2008-09-25
ES2446293T3 (es) 2014-03-07
IL200437A0 (en) 2010-04-29
MX2009010051A (es) 2009-10-12
PT2131860E (pt) 2014-03-04
US20090060924A1 (en) 2009-03-05
US7744874B2 (en) 2010-06-29
CR11004A (es) 2009-11-02
US20100221263A1 (en) 2010-09-02
JP5758933B2 (ja) 2015-08-05
RS53157B (en) 2014-06-30
CA2682212A1 (en) 2008-09-25
MY149129A (en) 2013-07-15
BRPI0809026A2 (pt) 2014-09-23
JP2010524846A (ja) 2010-07-22
SI2131860T1 (sl) 2014-02-28
CY1114784T1 (el) 2016-12-14
US7988970B2 (en) 2011-08-02
NZ578870A (en) 2012-01-12
EA200970874A1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
DOP2009000223A (es) Anticuerpos anti-esclerostina
CR11414A (es) Anticuerpos anti-hepcidina y usos de los mismos
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1123145T1 (el) Anti-cd40 αντισωματα
NL301196I2 (nl) inebilizumab
CO2018004532A2 (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112017010094A2 (pt) anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
AR088289A1 (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
NZ595235A (en) Compositions and methods for increasing muscle growth
GT200900002A (es) Anticuerpo antagonista para el tratamiento del cancer
HN2011001210A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
WO2009151717A3 (en) Bcr-complex-specific antibodies and methods of using same
CR20120577A (es) Anticuerpos hacia gdf8 humano
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
MY158481A (en) Compositions and methods for treating inflammatory disorders
AR073140A1 (es) Anticuerpos anti-il-23r disenados
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
EA201290977A1 (ru) Гуманизированные антитела к il-25
NZ595863A (en) Antibodies to egfl7 and methods for their use
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.